The UGT2B17 gene deletion is not associated with prostate cancer risk.
BACKGROUND
Deletion polymorphism of the UDP-glucuronosyltransferase 2B17 (UGT2B17) gene has been associated with an increased prostate cancer risk in two previous independent studies. Here we determine the risk in a large-scale population-based case-control study.


METHODS
Genotyping was conducted with a 5'-nuclease activity assay to distinguish those with one or two UGT2B17 gene copies (ins/del and ins/ins) from individuals homozygous for the deletion (del/del) allele.


RESULTS
In contrast to previous findings, no association between the UGT2B17 deletion polymorphism and prostate cancer risk was found. Furthermore the UGT2B17 gene deletion did not affect the risk for prostate cancer specific death.


CONCLUSIONS
The UGT2B17 deletion polymorphism does not play a major role in prostate cancer susceptibility as previously indicated.
Olsson
Mats
M
Department of Urology, Karolinska University Hospital, Stockholm, Sweden. mats.j.olsson@karlolinska.se
Lindström
Sara
S
Häggkvist
Benjamin
B
Adami
Hans-Olov
HO
Bälter
Katarina
K
Stattin
Pär
P
Ask
Birgitta
B
Rane
Anders
A
Ekström
Lena
L
Grönberg
Henrik
H
D000368:Aged; D016022:Case-Control Studies; D017353:Gene Deletion; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens; D011110:Polymorphism, Genetic / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics*; D012307:Risk Factors; D013548:Sweden
D015778:Minor Histocompatibility Antigens; D014453:Glucuronosyltransferase; C500513:UGT2B17 protein, human